Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris

Boris Duchemann, Isabella Annesi-Maesano, Camille Jacobe de Naurois, Shreosi Sanyal, Pierre-Yves Brillet, Michel Brauner, Marianne Kambouchner, Sophie Huynh, Jean Marc Naccache, Raphael Borie, Jacques Piquet, Arsène Mekinian, Jerôme Virally, Yurdagul Uzunhan, Jacques Cadranel, Bruno Crestani, Olivier Fain, Francois Lhote, Robin Dhote, Nathalie Saidenberg-Kermanac'h, Paul-André Rosental, Dominique Valeyre, Hilario Nunes, Boris Duchemann, Isabella Annesi-Maesano, Camille Jacobe de Naurois, Shreosi Sanyal, Pierre-Yves Brillet, Michel Brauner, Marianne Kambouchner, Sophie Huynh, Jean Marc Naccache, Raphael Borie, Jacques Piquet, Arsène Mekinian, Jerôme Virally, Yurdagul Uzunhan, Jacques Cadranel, Bruno Crestani, Olivier Fain, Francois Lhote, Robin Dhote, Nathalie Saidenberg-Kermanac'h, Paul-André Rosental, Dominique Valeyre, Hilario Nunes

Abstract

The objective of the study was to estimate the prevalence and incidence of interstitial lung diseases (ILDs) in Seine-Saint-Denis, a multi-ethnic county of Greater Paris, France.Patients with ILDs were identified between January and December 2012 by using several sources; all potentially involved medical specialists from public and private hospitals, community-based pulmonologists and general practitioners, and the Social Security system. Diagnoses were validated centrally by an expert multidisciplinary discussion.1170 ILD cases were reported (crude overall prevalence: 97.9/105 and incidence: 19.4/105/year). In the 848 reviewed cases, the most prevalent diagnoses were sarcoidosis (42.6%), connective tissue diseases associated ILDs (CTDs-ILDs) (16%), idiopathic pulmonary fibrosis (IPF) (11.6%), and occupational ILDs (5.0%), which corresponded to a crude prevalence of 30.2/105 for sarcoidosis, 12.1/105 for CTDs-ILDs and 8.2/105 for IPF. The prevalence of fibrotic idiopathic interstitial pneumonias, merging IPF, nonspecific interstitial pneumonia and cases registered with code J84.1 was 16.34/105 An adjusted multinomial model demonstrated an increased risk of sarcoidosis in North Africans and Afro-Caribbeans and of CTDs-ILDs in Afro-Caribbeans, compared to that in Europeans.This study, with a comprehensive recruitment and stringent diagnostic criteria, emphasises the importance of secondary ILDs, particularly CTDs-ILDs and the relatively low prevalence of IPF, and confirms that sarcoidosis is a rare disease in France.

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Copyright ©ERS 2017.

References

    1. J Pediatr. 1999 Sep;135(3):301-6
    1. Acta Clin Belg. 2001 May-Jun;56(3):163-72
    1. Am J Respir Crit Care Med. 2006 Oct 1;174(7):810-6
    1. Thorax. 2006 Nov;61(11):980-5
    1. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64
    1. Lancet Respir Med. 2014 Jul;2(7):566-72
    1. Eur Respir Rev. 2012 Dec 1;21(126):355-61
    1. Eur Respir J. 2015 Sep;46(3):795-806
    1. Eur Respir J. 2016 Jul;48(1):187-95
    1. Thorax. 2002 Apr;57(4):338-42
    1. PLoS One. 2014 Dec 30;9(12):e114871
    1. Am J Respir Crit Care Med. 1994 Oct;150(4):967-72
    1. Eur Respir J. 2016 Dec;48(6):1690-1699
    1. Respir Med. 2009 Aug;103(8):1122-9
    1. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):191-7
    1. Chest. 2010 Jan;137(1):129-37
    1. Ann Am Thorac Soc. 2016 Aug;13(8):1244-52
    1. Respir Med. 2012 Apr;106(4):588-93
    1. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
    1. Eur Respir J. 2015 Jul;46(1):186-96
    1. Lancet. 2012 Aug 18;380(9842):689-98
    1. Clin Respir J. 2014 Jan;8(1):55-62
    1. Arthritis Rheum. 2004 Feb 15;51(1):92-9
    1. PLoS One. 2016 Feb 03;11(2):e0147072
    1. Respir Med. 2012 Nov;106(11):1566-74
    1. Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
    1. Br J Cancer. 2006 Oct 23;95(8):966-73
    1. Am J Respir Crit Care Med. 2017 Mar 15;195(6):801-813
    1. Eur Respir J. 2016 Jul;48(1):179-86
    1. Eur Respir J Suppl. 2001 Sep;32:2s-16s
    1. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
    1. Respir Med. 2014 May;108(5):793-9

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren